At the time of writing, Takeda Pharmaceutical Co ADR [TAK] stock is trading at $14.27, up 0.49%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TAK shares have gain 4.93% over the last week, with a monthly amount drifted -4.99%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Takeda Pharmaceutical Co ADR [NYSE: TAK] stock has seen the most recent analyst activity on April 02, 2025, when Morgan Stanley upgraded its rating to a Overweight. Previously, BofA Securities upgraded its rating to Buy on March 16, 2023, and kept the price target unchanged to $20. On July 19, 2022, upgrade upgraded it’s rating to Outperform and revised its price target to $24 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight. JP Morgan downgraded its rating to a Neutral. Cowen started tracking with a Market Perform rating for this stock on November 01, 2019, and assigned it a price target of $19.50. In a note dated August 15, 2019, Daiwa Securities downgraded an Neutral rating on this stock.
For the past year, the stock price of Takeda Pharmaceutical Co ADR fluctuated between $12.80 and $15.53. Takeda Pharmaceutical Co ADR [NYSE: TAK] shares were valued at $14.27 at the most recent close of the market.
Analyzing the TAK fundamentals
According to Takeda Pharmaceutical Co ADR [NYSE:TAK], the company’s sales were 29.96B for trailing twelve months, which represents an -1.20% plunge. Gross Profit Margin for this corporation currently stands at 0.61% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.02 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Takeda Pharmaceutical Co ADR [NYSE:TAK] has a current ratio of 1.16. Also, the Quick Ratio is 0.59, while the Cash Ratio stands at 0.16. Considering the valuation of this stock, the price to sales ratio is 1.49, the price to book ratio is 0.94 and price to earnings (TTM) ratio is 48.26.
Transactions by insiders
Recent insider trading involved Thomas Wozniewski, Global Manufacturing & Supply, that happened on Jul 09 ’25 when 6136.0 shares were purchased. President, Global Oncology Bus, Teresa Marie Bitetti completed a deal on Jul 09 ’25 to buy 52649.0 shares. Meanwhile, President, Global Portfolio Di Ramona A Sequeira bought 0.1 million shares on Jul 09 ’25.
